Esterified estrogens (Estratab)

Drug Profile

Esterified estrogens (Estratab)

Alternative Names: Estratab

Latest Information Update: 12 Feb 2013

Price : $50

At a glance

  • Originator Solvay Pharmaceuticals
  • Developer Abbott Laboratories
  • Class Estradiol congeners; Hormonal replacements; Oral contraceptives
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Marketed Menopausal syndrome
  • Market Withdrawal Postmenopausal osteoporosis

Most Recent Events

  • 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott Laboratories
  • 17 Sep 2003 Withdrawn for Postmenopausal osteoporosis (prevention) in USA (PO)
  • 17 Sep 2003 Withdrawn for Menopausal syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top